# Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

> **NCT01410214** · PHASE2 · UNKNOWN · sponsor: **Chinese Lung Cancer Surgical Group** · enrollment: 80 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage IIIA

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** vinorelbine/cisplatin

## Key facts

- **NCT ID:** NCT01410214
- **Lead sponsor:** Chinese Lung Cancer Surgical Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-05
- **Primary completion:** 2015-07
- **Final completion:** 2017-07
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2011-12-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01410214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01410214, "Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01410214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*